Kalaris Therapeutics Inc. (NASDAQ:KLRS) Sees Large Decline in Short Interest

Kalaris Therapeutics Inc. (NASDAQ:KLRS) was the target of a large decline in short interest in April. As of April 15th, there was short interest totaling 842,687 shares, a decline of 15.3% from the March 31st total of 995,274 shares. Currently, 14.7% of the shares of the stock are short sold. Based on an average trading volume of 88,874 shares, the days-to-cover ratio is currently 9.5 days.

Analysts Set New Price Targets

Several equities research analysts have recently commented on KLRS shares. Morgan Stanley started coverage on Kalaris Therapeutics in a research note on Thursday, April 16th. They set an “overweight” rating and a $14.00 price target on the stock. Wall Street Zen raised Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Kalaris Therapeutics Price Performance

Shares of NASDAQ:KLRS opened at $5.46 on Friday. The business’s 50 day simple moving average is $7.44 and its 200-day simple moving average is $7.49. The firm has a market capitalization of $125.53 million, a price-to-earnings ratio of -1.30 and a beta of 0.15. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its earnings results on Tuesday, March 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.12. On average, equities analysts anticipate that Kalaris Therapeutics will post -2.18 earnings per share for the current year.

Institutional Investors Weigh In On Kalaris Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nano Cap New Millennium Growth Fund L P purchased a new stake in Kalaris Therapeutics in the 4th quarter valued at approximately $34,000. Barclays PLC purchased a new stake in Kalaris Therapeutics in the 4th quarter valued at approximately $51,000. Johnson Financial Group Inc. purchased a new stake in Kalaris Therapeutics in the 3rd quarter valued at approximately $58,000. XTX Topco Ltd purchased a new stake in Kalaris Therapeutics in the 2nd quarter valued at approximately $65,000. Finally, Keel Point LLC purchased a new stake in Kalaris Therapeutics in the 4th quarter valued at approximately $86,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.